The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. We will explore findings from our internal verification study, insights from early adopter sites, and real-world data that demonstrate how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges—delivering high analytical concordance with single-site testing.
We are also excited to welcome Leah Thompson, MB (ASCP)CM, Lab Technician at Tennessee Oncology, who will share her experience verifying and implementing MSK-ACCESS® powered by SOPHiA DDM™. She will discuss analytical performance, workflow simplicity, and the ease of integrating the solution into a laboratory setting.
Key Discussion Points:
- Decentralizing MSK-ACCESS® – Challenges and solutions for ensuring analytical accuracy, managing site variability, and optimizing workflows.
- Performance & Validation – How the SOPHiA DDM™ Platform maintains high concordance through advanced analytics, noise reduction, and standardized wet-lab processes.
- Real-World Adoption – Leah Thompson, MB (ASCP)CM shares insights on assay verification, workflow efficiency, and the ease of use in routine lab operations.
Learning Objectives
- Understand the Challenges of Decentralization – Learn about the complexities involved in decentralizing MSK-ACCESS® and how the SOPHiA DDM™ Platform addresses key hurdles such as analytical accuracy, wet-lab standardization, and noise reduction.
- Evaluate Performance and Real-World Verification – Gain insights into the internal verification study results and real-world data from seven early adopter sites, demonstrating high analytical concordance between the decentralized and single-site versions of MSK-ACCESS®
- Explore Ease of Adoption and Workflow Efficiency – Understand how MSK-ACCESS® powered with SOPHiA DDM™ offers a streamlined workflow, reliable data quality, and a straightforward implementation process for laboratories.
Explore the Impact on Precision Oncology – Discover how the successful adoption of a decentralized liquid biopsy solution fosters community-driven insights, continuously improving variant calling algorithms and expanding access to high-quality genomic testing.